Provectus Pharmaceuticals Completes Patient Accrual In Initial Phase 2 Study Of PH-10 For Atopic Dermatitis
Jul 02, 2009 -- Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual for its Phase 2 study of PH-10 for atopic dermatitis. PH-10 is the Company's topical drug for the treatment of dermatologic diseases, including atopic dermatitis, a chronic skin condition that includes some forms of eczema.
|
Take Care Health Systems Expands Treatment For Skin Conditions And Minor Injuries
Jul 02, 2009 -- Take Care Health Systems, a wholly-owned subsidiary of Walgreens (NYSE:WAG) (NASDAQ:WAG) and the largest and most comprehensive provider of convenient care clinics and worksite health and wellness centers in the country, is now offering a new set of procedures for skin conditions and minor injury treatments.
|
New Treatment For Receding Gums: No Pain, Lots Of Gain
Jul 02, 2009 -- Tufts dental researchers conducted a three-year follow-up study that examined the stability of a treatment option for receding gums and found that complete root coverage the goal of the surgery had been maintained. This specific tissue regeneration application, developed at Tufts, reduces the considerable pain and recovery time of gum grafting surgery. The case study of six patients is published in the July 2009 issue of the Journal of Periodontology.
|
Men And Women Find Cosmetic Surgery Appealing When They Suffer Appearance-Based Rejection Sensitivity
Jul 02, 2009 -- Researchers have found that men and women who feel sensitive to rejection based on their physical appearance are more likely to express interest in having cosmetic surgery than those who are less sensitive to appearance-based rejection. This effect is particularly true when people recall negative comments about their physical appearance. The study, which appeared in the June issue of the journal Body Image, was conducted by Lora E. Park, Ph.D.
|
|
|